Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

791 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial.
McCartney A, Bonechi M, De Luca F, Biagioni C, Curigliano G, Moretti E, Minisini AM, Bergqvist M, Benelli M, Migliaccio I, Galardi F, Risi E, De Santo I, Romagnoli D, Biganzoli L, Di Leo A, Malorni L. McCartney A, et al. Among authors: di leo a. Clin Cancer Res. 2020 May 1;26(9):2131-2139. doi: 10.1158/1078-0432.CCR-19-3271. Epub 2020 Jan 14. Clin Cancer Res. 2020. PMID: 31937617 Free article. Clinical Trial.
Chemotherapy for metastatic breast cancer.
Biganzoli L, Minisini A, Aapro M, Di Leo A. Biganzoli L, et al. Among authors: di leo a. Curr Opin Obstet Gynecol. 2004 Feb;16(1):37-41. doi: 10.1097/00001703-200402000-00008. Curr Opin Obstet Gynecol. 2004. PMID: 15128006 Review.
Using specific cytotoxics with a targeted mind.
Di Leo A, Claudino WM, Pestrin M, Licitra S, Biganzoli L. Di Leo A, et al. Breast. 2007 Dec;16 Suppl 2:S120-6. doi: 10.1016/j.breast.2007.07.021. Epub 2007 Aug 27. Breast. 2007. PMID: 17720501 Review.
Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel.
Galmarini CM, Treilleux I, Cardoso F, Bernard-Marty C, Durbecq V, Gancberg D, Bissery MC, Paesmans M, Larsimont D, Piccart MJ, Di Leo A, Dumontet C. Galmarini CM, et al. Among authors: di leo a. Clin Cancer Res. 2008 Jul 15;14(14):4511-6. doi: 10.1158/1078-0432.CCR-07-4741. Clin Cancer Res. 2008. PMID: 18628466 Clinical Trial.
Taxanes in the elderly: can we gain as much and be less toxic?
Biganzoli L, Licitra S, Moretti E, Pestrin M, Zafarana E, Di Leo A. Biganzoli L, et al. Among authors: di leo a. Crit Rev Oncol Hematol. 2009 Jun;70(3):262-71. doi: 10.1016/j.critrevonc.2008.07.017. Epub 2008 Aug 30. Crit Rev Oncol Hematol. 2009. PMID: 18762431 Review.
Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.
Di Leo A, Gomez HL, Aziz Z, Zvirbule Z, Bines J, Arbushites MC, Guerrera SF, Koehler M, Oliva C, Stein SH, Williams LS, Dering J, Finn RS, Press MF. Di Leo A, et al. J Clin Oncol. 2008 Dec 1;26(34):5544-52. doi: 10.1200/JCO.2008.16.2578. Epub 2008 Oct 27. J Clin Oncol. 2008. PMID: 18955454 Free PMC article. Clinical Trial.
791 results